Hanmi Pharm said Friday that the cumulative sales of Mok-N Spray, an over-the-counter drug for treating sore throat that was first launched in 2015, exceeded 3.91 million units.

Mok-N sold more than 210,000 units in 2015, the first year of its launch, and it began to grow rapidly from the beginning of 2020, when the Covid-19 pandemic was in full swing, with more than 820,000 units sold in 2022 alone.

According to the company, Mok-N helps relieve symptoms such as sore throat, hoarseness, and canker sores by combining the inflammatory effects of water-soluble azulene and the antibacterial effects of cetylpyridinium chloride (CPC).

In particular, Mok-N is packaged in a specially designed German container that prevents bacterial invasion from outside and does not contain any preservatives, representing its safety for children, pregnant women, and nursing mothers who need to be careful when using medications, said Hanmi Pharm.

When used for throat inflammation, Mok-N can be sprayed three to five times a day, three to four times per use.

"Due to the spread of various pandemics, rapidly changing weather conditions, and air pollution, demands for treating neck pain are continuously increasing," said a Hanmi Pharm official. "We hope that Mok-N Spray, which can be used easily to care for neck pain, will help treat patients."